medicina55巻3号

2018年03月発行

特集 —クリニカル・クエスチョンで学ぶ—循環器薬の使い方 不整脈患者に使用する薬

心房細動では抗不整脈薬やアブレーションでリズムコントロールしたほうがよいですか？

著者： 藤原竜童¹

所属機関： ¹大阪府済生会中津病院循環器内科

ページ範囲：P.441 - P.445

　下記のQuestionに対する回答は「ケースバイケース」である．
　回答の難しさの所以は，心房細動そのものの多様性と，心房細動を発症した患者背景の多様性にある．

参考文献

1）Berger M, et al：Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter；A retrospective analysis. Am J Cardiol 82：1545-1547, 1998

2）Cardiac Arrhythmia Suppression Trial（CAST）Investigators：Preliminary report；Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321：406-412, 1989

3）Siontis KC, et al：Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community；Characteristics and prognostic implications. Heart Rhythm 13：1418-1424, 2016

4）Boriani G, et al：Asymptomatic atrial fibrillation；Clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med 128：509-518, 2015

5）Ogawa S, et al：Optimal treatment strategy for patients with paroxysmal atrial fibrillation；J-RHYTHM Study. Circ J 73：242-248, 2009

6）Odutayo A, et al：Atrial fibrillation and risks of cardiovascular disease, renal disease, and death；Systematic review and meta-analysis. BMJ 354：i4482, 2016

7）Wyse DG, et al：A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347：1825-1833, 2002

8）Carlsson J, et al：Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation；The Strategies of Treatment of Atrial Fibrillation（STAF）study. J Am Coll Cardiol 41：1690-1696, 2003

9）Roy D, et al：Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358：2667-2677, 2008

10）Jaïs P, et al：Catheter ablation versus antiarrhythmic drugs for atrial fibrillation；The A4 study. Circulation 118：2498-2505, 2008

11）Tilz RR, et al：Catheter ablation of long-standing persistent atrial fibrillation；5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol 60：1921-1929, 2012

12）Miyazaki S, et al：Preprocedural predictors of atrial fibrillation recurrence following pulmonary vein antrum isolation in patients with paroxysmal atrial fibrillation；Long-term follow-up results. J Cardiovasc Electrophysiol 22：621-625, 2011

13）Friberg L, et al：Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death；Data from Swedish health registries. Eur Heart J 37：2478-2487, 2016

14）Kato T, et al：Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. Circ J 68：568-572, 2004

15）Van Gelder IC, et al：Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 38：1339-1344, 2017

16）Al-Khatib SM, et al：Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation；Results from the ARISTOTLE trial. Eur Heart J 34：2464-2471, 2013

17）Probst J, et al：Thoracoscopic epicardial left atrial ablation in symptomatic patients with atrial fibrillation. Europace 18：1538-1544, 2016

18）Ohtsuka T, et al：Thoracoscopic stand-alone left atrial appendectomy for thromboembolism prevention in nonvalvular atrial fibrillation. J Am Coll Cardiol 62：103-107, 2013